Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about SANOFI
09:28aSANOFI : Sell rating from Deutsche Bank
MD
10/25SANOFI : Regeneron's Second Late-Stage Inflammatory Disease Trial Meets Primary Endpoints
MT
10/25SANOFI : Regeneron's Dupixent Improves Swallowing in Late-Stage Study
MT
10/25Second Dupixent? Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Dise..
CI
10/22SANOFI : JP Morgan keeps its Buy rating
MD
10/22SANOFI : Regeneron's Dupixent Meets Primary, Key Secondary Endpoints in Phase 3 Trial in P..
MT
10/22SANOFI : Regeneron's Dupixent Cuts Itch in Late-Stage Skin Disease Study
MT
10/22SANOFI : Dupixent« (dupilumab) is the first biologic to significantly reduce itch and skin..
AQ
10/22Regeneron Pharmaceuticals, Inc. and Sanofi Announces Positive Pivotal Phase 3 Results f..
CI
10/21SANOFI : Gets a Buy rating from UBS
MD
10/20SANOFI : Regeneron Win Expanded US FDA Nod for Asthma Drug Dupixent
MT
10/20SANOFI : says its flu vaccine can be co-administered with Moderna's COVID-19 shot
RE
10/15SANOFI : New long-term data reinforcing promising safety and efficacy profile of brain-pen..
PU
10/15Sanofi Announces New Long-Term Data Reinforcing Promising Safety and Efficacy Profile o..
CI
10/14SANOFI : Goldman Sachs keeps its Buy rating
MD
More most relevant news
All news about SANOFI
09:28aSANOFI : Sell rating from Deutsche Bank
MD
08:00aPRESS RELEASE : BioNTech Plans to Initiate the Construction of an mRNA Vaccine Manufacturi..
DJ
01:49aPRESS RELEASE : Evotec provides preliminary nine month financial results
DJ
10/25REGENERON PHARMACEUTICALS : Second dupixent (dupilumab) phase 3 eosinophilic esophagitis t..
AQ
10/25SANOFI : Regeneron's Second Late-Stage Inflammatory Disease Trial Meets Primary Endpoints
MT
10/25SANOFI : Regeneron's Dupixent Improves Swallowing in Late-Stage Study
MT
10/25Second Dupixent? Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Dise..
CI
10/22SANOFI : JP Morgan keeps its Buy rating
MD
10/22SANOFI : Regeneron's Dupixent Meets Primary, Key Secondary Endpoints in Phase 3 Trial in P..
MT
10/22REGENERON, SANOFI : Dupixent Hits Main Endpoints in Prurigo Nodularis Trial
DJ
More news
News in other languages on SANOFI
10:31aBEURSAGENDA : buitenlandse fondsen
08:00aGlobeNewswire/BioNTech plant Mitte 2022 den Baubeginn einer mRNA Impfstoff-Produktionss..
02:18aEvotec sieht 9M-EBITDA unter Vj, Konzernerlös deutlich höher
02:16aEvotec wächst weiter - Produktionsstart in den USA drückt auf Ergebnis
01:49aEvotec veröffentlicht vorläufiges Finanzergebnis für die ersten neun Monate 2021
12:48aBEURSAGENDA : buitenlandse fondsen
10/26Agenda FRANCE & INTERNATIONAL À 7 JOURS
10/25BEURSAGENDA : buitenlandse fondsen
10/25Agenda AOF / Sociétés France - Semaine du lundi 25 octobre 2021
10/25Le deuxième essai de Sanofi et Regeneron sur les maladies inflammatoires de stade avanc..
More news
Analyst Recommendations on SANOFI
09:28aSANOFI : Sell rating from Deutsche Bank
MD
10/22SANOFI : JP Morgan keeps its Buy rating
MD
10/21SANOFI : Gets a Buy rating from UBS
MD
10/14SANOFI : Goldman Sachs keeps its Buy rating
MD
10/14SANOFI : JP Morgan keeps its Buy rating
MD
More recommendations
Press releases
10/25REGENERON PHARMACEUTICALS : Second dupixent (dupilumab) phase 3 eosinophilic esophagitis t..
AQ
10/22SANOFI : Dupixent« (dupilumab) is the first biologic to significantly reduce itch and skin..
AQ
10/21REGENERON PHARMACEUTICALS : Fda expands approval of dupixent (dupilumab) to include childr..
AQ
10/15SANOFI : New long-term data reinforcing promising safety and efficacy profile of brain-pen..
PU
10/13SANOFI : Update from Sanofi regarding Kevzara (sarilumab) - Supply constraints anticipated..
AQ
More press releases
Upcoming event on SANOFI